NCT06799520Phase 1Active, not recruiting
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 1
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Participants (registry)
- 30
- Start
- March 2025
- Primary completion
- October 2026 (planned)
- Study completion
- February 2027 (planned)
- Last registry update
- July 2026
- Countries
- Bulgaria, Moldova, Romania, Spain
Conditions studied: Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Interventions: VIS171
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.